Login / Signup

Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer.

Joseph A DottinoKatharine M EsselenRebecca CostaStephanie ArgetsingerMahnum ShahzadDennis Ross-DegnanAnita K Wagner
Published in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
Potential patient harm, including financial toxicity, might have been mitigated through more stringent drug approval requirements.
Keyphrases
  • oxidative stress
  • case report
  • affordable care act
  • healthcare
  • risk assessment
  • protein kinase
  • human health
  • health insurance
  • drug administration
  • drug induced
  • structural basis
  • climate change